Oxaliplatin News and Research

RSS
The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Genes could help physicians make informed treatment decisions for metastatic colorectal cancer patients

Genes could help physicians make informed treatment decisions for metastatic colorectal cancer patients

Study quantifies different mutational profiles of tumour cell clusters in patients with bowel cancer

Study quantifies different mutational profiles of tumour cell clusters in patients with bowel cancer

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Novel combination therapy shows promise in mouse models of advanced prostate cancer

Novel combination therapy shows promise in mouse models of advanced prostate cancer

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Uninsured cancer patients may face higher charges for chemotherapy drugs

Uninsured cancer patients may face higher charges for chemotherapy drugs

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

EMA extends approval of Vectibix plus FOLFIRI as first-line treatment for wild-type RAS mCRC

EMA extends approval of Vectibix plus FOLFIRI as first-line treatment for wild-type RAS mCRC

Chinese researchers achieve major breakthrough in nano-carrier drugs for pancreatic cancer

Chinese researchers achieve major breakthrough in nano-carrier drugs for pancreatic cancer

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

XenOPAT aims to advance development of new drugs against cancer, personalized cancer treatments

XenOPAT aims to advance development of new drugs against cancer, personalized cancer treatments

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Adopting a comprehensive and integrative healing strategy for cancer

Adopting a comprehensive and integrative healing strategy for cancer

Phase III TAS-102 study for metastatic colorectal cancer shows improved survival

Phase III TAS-102 study for metastatic colorectal cancer shows improved survival

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

SLU researchers discover pain pathway and potential way to block it

SLU researchers discover pain pathway and potential way to block it

Amgen presents extended analysis of PEAK study data at ASCO

Amgen presents extended analysis of PEAK study data at ASCO

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.